Assertio Logo.jpg
Assertio Reports Second Quarter 2020 Financial Results
August 07, 2020 06:02 ET | Assertio Therapeutics, Inc.
--Completed all merger and integration activities in Q2----Repaid $10 million of Senior Secured Notes ahead of schedule-- --Zyla products partially contributed to Q2 net product sales of $20.2...
Assertio Logo.jpg
Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020
July 20, 2020 06:02 ET | Assertio Therapeutics, Inc.
LAKE FOREST, Ill., July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020...
Assertio Logo.jpg
Assertio Therapeutics Announces First-Quarter 2020 Results
May 11, 2020 08:00 ET | Assertio Therapeutics, Inc.
-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger...
Assertio Logo.jpg
Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus
April 20, 2020 17:08 ET | Assertio Therapeutics, Inc.
 Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting Assertio Reaffirms its Ability to Achieve Upwards of $40 Million in Synergies Will Report First...
Assertio Logo.jpg
Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024
April 08, 2020 16:05 ET | Assertio Therapeutics, Inc.
LAKE FOREST, Ill., April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash tender...
Assertio Logo.jpg
Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products
March 16, 2020 18:45 ET | Assertio Therapeutics, Inc.
Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue...
Assertio Logo.jpg
Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024
March 11, 2020 01:01 ET | Assertio Therapeutics, Inc.
LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the...
Assertio Logo.jpg
Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results
March 09, 2020 16:02 ET | Assertio Therapeutics, Inc.
 -- Reports Neurology Franchise Annual Net Sales of $108.1 Million, Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5...
Assertio Logo.jpg
Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020
March 02, 2020 17:30 ET | Assertio Therapeutics, Inc.
LAKE FOREST, Ill., March 02, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced that it will release fourth quarter and full year 2019...
Assertio Logo.jpg
Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt
February 19, 2020 08:00 ET | Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced it has entered into separate, privately negotiated...